Cost-Effectiveness Analysis on the Use of Recombinant Human Erythropoietin among Hemodialysis Patients
碩士 === 義守大學 === 管理研究所碩士班 === 96 === Anemia is one of the common problems among patients with chronic kidney disease, and one of the important parameters of dialysis quality measurement. Artificially synthesized erythropoietin (Recombinant human Erythropoietin, rHuEPO) can treat the renal anemia effe...
Main Authors: | Li-Yin Huang, 黃力尹 |
---|---|
Other Authors: | Jeremy Ying |
Format: | Others |
Language: | zh-TW |
Published: |
2008
|
Online Access: | http://ndltd.ncl.edu.tw/handle/27678305470264885195 |
Similar Items
-
Recombinant human erythropoietin treatment of anemia in hemodialysis patients
by: Cinthya M. Ozawa, et al.
Published: (2007-05-01) -
Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients
by: Kristina Petrulienė, et al.
Published: (2017-01-01) -
Characteristics of erythropoietin antibodies in patients treated with recombinant human erythropoietin
by: A. M. Kudryashova, et al.
Published: (2020-01-01) -
Influence of hemoglobin level and dose of administered recombinant human beta erythropoietin on survival of hemodialysis patients
by: Knežević Violeta, et al.
Published: (2011-01-01) -
The efficacy of darbepoetin alpha in hemodialysis patients resistant to human recombinant erythropoietin (rHuEpo)
by: Hejaili Fayez
Published: (2009-01-01)